Treatment with teriparatide might be associated with cardiometabolic changes in postmenopausal severe osteoporotic women.

@article{Passeri2015TreatmentWT,
  title={Treatment with teriparatide might be associated with cardiometabolic changes in postmenopausal severe osteoporotic women.},
  author={Elena Passeri and Elena Dozio and Marco Mendola and Elena Costa and Francesco Bandera and Massimiliano Marco Corsi Romanelli and Sabrina Corbetta},
  journal={Journal of biological regulators and homeostatic agents},
  year={2015},
  volume={29 4},
  pages={931-40}
}
Parathormone (PTH) has been suggested to affect the cardiovascular system. Teriparatide (TPT), the hormonally active 1-34 fragment of PTH, provides an anabolic treatment for osteoporosis. The aim of the present study was to evaluate the cardiometabolic effects of 18-month treatment with 20 μg/ die teriparatide subcutaneosly. Fourteen women with postmenopausal severe osteoporosis treated with once-daily sc 20 μg TPT (67.6 ± 2.5 years; BMI 27.7 ± 1.0 kg/m²) and 24 age- and BMI-matched severe… CONTINUE READING

Similar Papers

Loading similar papers…